ximelagatran


Also found in: Wikipedia.

ximelagatran

An oral direct thrombin inhibitor drug used as an anticoagulant alternative to warfarin in the management of thromboembolism. In late 2004 the American FDA rejected an application for approval of this drug on the grounds of liver toxicity.
References in periodicals archive ?
Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res.
Stroke prevention with aspirin, warfarin, and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis.
A 2013 meta-analysis of 5 RCTs including 51,895 patients with nonvalvular atrial fibrillation compared the efficacy and safety of the NOACs dabigatran, rivaroxaban, apixaban, and ximelagatran, with the efficacy and safety of warfarin.
Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: A systematic review and meta-analysis.
Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
(8,13) However, a similar signal of increased cardiac events and MI was also observed with another DTI, ximelagatran. (14)
Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial.
Nuevas moleculas actualmente en fases de experimentacion clinica son los inhibidores selectivos de la trombina de administracion parenteral (desirudin, lepirudin, bivalirudin, argatroban) y oral (ximelagatran y dabigatran etexilate) y los inhibidores orales del factor Xa (rivaroxaban, razaxaban y apixaban) [2,48].
Edwards, "Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis, "Thrombosis Research, vol.118, no.3, pp.321-333, 2006.
Another direct thrombin inhibitor, ximelagatran, did not show advantages over other anticoagulants and it was withdrawn from the market.